Wall Street is having a rough week in Washington, D.C.
Just one day after Wells Fargo's (WFC - Get Report) CEO John Stumpf was raked over the coals by the Senate Committee on Oversight on Tuesday, Mylan's (MYL - Get Report) CEO Heather Bresch appeared in the House of Representatives to testify on the rising prices of EpiPens.
Both Democrat and Republican representatives on the House Oversight and Government Reform Committee pressed Bresch and Doug Thockmorton, a representative from the Food and Drug Administration, on the cost of EpiPen and it's lack of competitors in the pharmaceutical industry.
The grilling was intense. So much so that one Wall Street analyst, when reached via email, called it "painful."
"Would you agree that you made hundreds of millions of dollars in profit in 2015 based on the sale of EpiPens alone?" Rep. Elijah Cummings (D-Md.) asked Bresch at the hearing.
"Sir, we have an $11 billion company. I run an $11 billion company. And yes, EpiPen is our largest product, but [it's] by no means driving the entire performance of our company," she answered.
"No, answer my question. So you agree that you made hundreds of millions of dollars in profit in 2015 based on the sale of EpiPens?" he asked again.
"Yes sir," she admitted.
The hearing was the culmination of the federal government's efforts to make the pharmaceutical giant pay for boosting prices of its epinephrine auto injector, used as an emergency rescue drug for anaphylaxis, since 2007.
EpiPen prices reached approximately $600 per two pack this year, although most patients pay significantly less for the drug. Still, Mylan stole the spotlight as the latest in a string of drug companies that have bolstered prices and as a result, gouged consumers.
Mylan boosted prices approximately 25% each year, as compared to the drug industry's average of 10% yearly price increase.
Leerink analyst Jason Gerberry wrote in a note that the hearing was "contentious" but that "no tangible outcomes are likely to result from the hearing."
Bresch was also questioned on her mother, Gayle Manchin's involvement with the EpiPen 4 Schools program. In 2012 Manchin served as head of the National Association of State Boards of Education, and reportedly pushed the board to push schools to stock EpiPens.
Bresch called the allegations about her mother "inaccurate" adding that "while people may want to criticize Mylan for giving free pens and having access in public places to Epipens, I certainty thought it was a very cheap shot to bring my mother into this."
Another major sticking point for the representatives was Bresch's salary. Bresch, who has worked as the CEO for Mylan since 2012, made $18 million last year.
When asked what her salary was like in comparison to others in the drug industry, Bresch said her salary was "in the middle." A Wall Street Journal analysis showed, though, that Mylan's executive compensation ranks second in the drug industry, despite its comparatively small market cap.
Representatives disagreed, and brought up that number several times during the hearing.
Mylan, which has a market cap of $22.42, closed at $41.91 per share Wednesday, up 1.6% from market's open.
EDITORS' NOTE: This story was originally published at 4:57 pm, Sept. 21. It has been updated to include additional comments from the hearing.